TMCnet News
Vineti introduces new PTM® Integration Suite: purpose-built connectivity and interoperability for cell and gene therapies
SAN FRANCISCO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Vineti, developer of the leading digital platform of record for personalized therapeutics, today announced a new Integration Suite as a cornerstone of its Personalized Therapy Management® (PTM) solution. This API-based PTM® Integration Suite delivers purpose-built connectivity for orchestrating cell and gene therapy systems, ultimately speeding and simplifying workflows and providing better care for patients.. “In cell and gene therapy, no one part of the process can move ahead on its own,” said Vineti CEO and Co-founder Amy DuRoss. “Unlike traditional therapeutics, patient information is required at every step in cell and gene therapy. This Integration Suite enables this new level of interoperability and transparency for cell and gene therapies, so that more patients can receive the right life-saving treatment at the right time.” Cell and gene therapies, such as CAR-T cell therapies, are produced via the most complex supply chain in the history of medicine, with rigorous regulatory requirements every step of the way. Manufacturing batches are typically small — often just one single patient-specific product per batch — and rely on highly interconnected workflows in which patient-related data must be passed between multiple stakeholders, dozens or hundreds of times, for every single patient and product. Each of these data exchanges must not only happen smoothly, but must be traceable, trackable, controllable, and precisely documented to satisfy regulatory requirements. Keeping each patient product moving quickly, safely, and compliantly demands digital solutions and a focused, secure approach to integrations. As the leader in advanced therapy value chain orchestration technology, Vineti knows first-hand that these transformative therapies require purpose-built integrations. Vineti’s API-based Integration Suite solves critical supply chain integration challenges that can otherwise hiner advanced therapies and keep some patients — including those facing cancer or rare genetic disorders — from receiving the personalized treatments they need. Through APIs, the PTM® Integration Suite enables authorized third-party applications to programmatically enter and/or retrieve patient and treatment order data. The PTM® Integration Suite currently focuses on three core APIs – a Patient API, Order API, and Schedule API – with more to follow in ongoing PTM® releases. Each PTM® API enables a requirement unique to cell and gene therapies – patient-related data is necessary at multiple points in every workflow, making integrations, interoperability, and data integrity essential. The PTM® Integration Suite is available from Vineti’s Business Development team, and is built into Vineti’s industry-leading PTM® Platform solution for cell and gene therapy supply chain management. Additional solution information
About Vineti’s PTM® Platform About Vineti Media Contacts Dan Budwick, 1AB Media (for Vineti) ![]() |